Abstract TMP105: Migraine With Aura Risk Score, Medication Use And Composite Cardiovascular

• Published in: Stroke (1970) 2023-02, Vol.54 (Suppl_1), p.ATMP105-ATMP105
• Main Authors: McCain, Caylee, Martin, Chylee, Kerley, John, Logue, Makenzie, Trivedi, Tushar, Melikov, Petr, Gottesman, Rebecca F, Rosamond, Wayne D, Sen, Souvik
• Format: Article
• Language: English
• ISSN: 0039-2499; 1524-4628
• DOI: 10.1161/str.54.suppl_1.TMP105

BackgroundThe migraine with aura risk score (MARS) was developed to predict the risk of ischemic stroke in patients with migraine with aura. Certain medications (estrogen replacement therapy-ERT, triptans and ergot alkaloids) have been postulated to increase cardiovascular risk. We tested if MARS or medications increased risk of ischemic stroke, cardiovascular event, and death. MethodsMigraine with aura patients (N=430) in the Atherosclerosis Risk in Communities Cohort were considered in this study. Those who had events prior to being evaluated were excluded leaving 420 patients. MARS was calculated at visit 3 (1993-1995) and patients were stratified as low (≤2) and high (≥3) risk groups. Medication uses were recorded on the same visit. ResultsOf the 420 patients with a history of migraine with aura (age, mean±standard deviation=58.5±5.5, 349 female, 344 white), 49 patients had an ischemic stroke, 79 had a cardiovascular event, and 192 died during a 25-year follow-up period. The high-risk group was noted to have hazards ratio (HR) of 4.41 (95% CI 2.45-7.94) for ischemic stroke, 5.89 (95% CI 3.69-9.38) for cardiovascular event, and 3.56 (95% CI 2.66-4.79) for death, compared with the low-risk group. HR for composite events was 3.60 (95% CI 2.73-4.75). Kaplan-Meier Survival curves are depicted below (Logrank p